argenx Unnatural Products Acquisition: Inside the $1.15B Bet on Oral Peptides

The argenx Unnatural Products acquisition, announced on 9 November 2026, will see the Vyvgart maker buy Santa Cruz, California-based Unnatural Products (UNP) for up to US$1.15 billion, including US$550 million in cash upfront and up to US$595 million in milestones. The deal converts an existing minority stake and a 2025 research pact into full ownership of a platform that designs oral macrocyclic peptides, and it is expected to close before the end of 2026.

Key takeaways on argenx Unnatural Products acquisition

• Total value up to US$1.15 billion: US$550 million upfront plus up to US$595 million contingent on milestones.
• argenx already held a minority stake and had a multi-target collaboration with UNP since July 2025.
• The prize is a discovery engine for pill-form peptides able to hit targets usually reserved for injected antibodies.
• It is argenx’s second acquisition of 2026, after the roughly US$2.2 billion Forte Biosciences deal.
• argenx shares rose almost 3% on the announcement day.

Deal at a glance

By our calculation, the guaranteed portion is about 48% of the headline value, a relatively high upfront share for a preclinical platform deal and a sign that argenx had already seen enough data through the collaboration to pay for certainty rather than options.

From partner to owner in 16 months

In July 2025, UNP and argenx signed a research collaboration under which UNP would discover oral peptide candidates up to IND-enabling studies, with argenx holding exclusive options to develop them. Reports at the time and since have pointed to an oral FcRn inhibitor as one of the targets, which would be a natural complement to argenx’s injectable FcRn franchise. Buying the company outright removes per-target option fees and royalties, secures the team (UNP will keep operating from Santa Cruz) and keeps the platform away from rivals. It also ends the platform’s availability to argenx’s competitors on new programmes, though the treatment of UNP’s existing pacts with MSD, Novartis and BridgeBio was not detailed in the reports we reviewed.

What macrocyclic peptides are, in plain terms

Macrocyclic peptides are ring-shaped chains of amino acids. They are larger than classic small-molecule pills, which lets them grip the broad, flat protein surfaces that small molecules struggle to block, yet small enough that, with careful engineering, they can be absorbed when swallowed. UNP’s approach combines AI-guided design, parallel chemical synthesis and direct-to-biology screening to find ring structures that are both potent and orally available. The hard part, historically, has been getting enough drug through the gut wall; that is where the platform’s value will be tested.

The strategic logic: an oral future for an injectable franchise

argenx’s growth has come from Vyvgart (efgartigimod), which generated about US$4.5 billion in net product sales in the first nine months of 2026, chiefly in generalized myasthenia gravis. By our calculation, the upfront payment equals roughly 12% of those nine-month sales, an affordable bet for a company of argenx’s scale. Chief executive Karen Massey called UNP’s peptide capabilities “highly complementary” to argenx’s antibody engineering. The long-term concern for any injectable franchise is that a once-daily pill hitting the same pathway could change prescribing habits; owning such a platform is a hedge against that and an opening into new immune targets. Leerink Partners analyst Thomas Smith described the move as offering potential longer-term strategic value, citing industry demand for oral, long-acting therapies.

Market context

Myasthenia gravis is the anchor indication that funds argenx’s expansion. Acumen Research and Consulting’s myasthenia gravis treatment market report sized the global market at US$1.3 billion in 2022 and projects US$2.6 billion by 2032, a CAGR of 7.3% from 2023, with North America the largest region and Asia-Pacific the fastest growing. IVIg held the largest drug-class share in 2022, which shows how much room targeted biologics and, potentially, oral alternatives still have to take share. For more on this space, see our myasthenia gravis treatment market analysis.

Risks and unanswered questions

• Platform risk. No UNP-derived oral peptide has yet proven itself in late-stage human trials in the reports we reviewed; oral bioavailability that works in animals can disappoint in people.
• Milestone details. The triggers for the US$595 million in contingent payments were not disclosed.
• Integration. Two acquisitions in one year stretch management attention at a company still scaling Vyvgart globally.
• Third-party pacts. How existing UNP partnerships with other drugmakers will be handled has not been made public.

Peptide capacity is a hot theme across the industry, from discovery engines like UNP to manufacturing expansions such as Shilpa CDMO’s peptide investment in India. More deal coverage is in our Industry Insights section.

People also ask

How much is argenx paying for Unnatural Products?

Up to about US$1.15 billion: US$550 million in cash at closing and up to US$595 million in milestone payments.

Why did argenx buy Unnatural Products?

To own a platform for oral macrocyclic peptides that could deliver pill-form medicines for immune diseases, complementing its injectable antibody portfolio led by Vyvgart.

When will the argenx deal close?

The companies expect closing before the end of 2026, subject to customary conditions.

What is a macrocyclic peptide drug?

A ring-shaped peptide engineered to bind protein targets that small molecules cannot easily reach, while remaining small enough to potentially be taken by mouth.

Sources: BioPharma Dive and pharmaphorum (9 November 2026), Unnatural Products collaboration announcement (1 July 2025). Market data: Acumen Research and Consulting. This article is for information only and is not investment advice. Last updated 11 November 2026.